Overview Performance Dividends Peer Group Options

(RFL) Rafael Holdings - Ratings and Ratios

Exchange: NYSE • Country: United States • Currency: USD • Type: Common Stock • ISIN: US75062E1064

RFL: Cancer, Drugs, Real, Estate

Rafael Holdings, Inc. (NYSE:RFL) is a holding company with diversified interests in clinical-stage pharmaceuticals and commercial real estate across the United States and Israel. The company operates through three primary segments: Healthcare, Infusion Technology, and Real Estate. Its healthcare division focuses on therapies targeting metabolic differences between cancer and normal cells. The lead drug candidate, CPI-613 (devimistat), is in Phase 2 trials for advanced solid cancers, including colorectal and pancreatic cancers, in combination with existing chemotherapies. Additional pipeline assets include Promitil, a mitomycin-C prodrug, and Promi-Dox, a dual-drug liposome for various tumors.

The company also develops surgical devices, such as orthopedic arthroscopy instruments for Carpal Tunnel syndrome. Real estate holdings provide diversification and cash flow stability. Incorporated in 2017 and headquartered in Newark, New Jersey, Rafael Holdings trades on the NYSE with a market capitalization of approximately $50.53 million. Its stock has shown recent price weakness, trading below its 20-day and 50-day moving averages.

Based on and , Rafael Holdings, Inc. (RFL) is expected to face headwinds in the next 3 months. The stock price, currently at $1.88, is below its SMA 20 ($2.01) and SMA 50 ($1.96), indicating bearish momentum. The average true range (ATR) of 0.11 suggests moderate volatility. With a price-to-book ratio of 0.69 and negative return on equity (-54.11%), the stock may struggle to attract buyers. The 3-month price target is projected to range between $1.60 and $1.80, reflecting potential downside risks.

Additional Sources for RFL Stock

News: Wall Street Journal Benzinga Yahoo Finance
Tweets: X Stocktwits
Fund Manager Positions: Dataroma Stockcircle

RFL Stock Overview

Market Cap in USD 46m
Sector Real Estate
Industry Real Estate Services
GiC Sub-Industry Real Estate Development
IPO / Inception 2018-03-26

RFL Stock Ratings

Growth 5y -54.4%
Fundamental -64.8%
Dividend 0.0%
Rel. Strength Industry -2.07
Analysts -
Fair Price Momentum 1.37 USD
Fair Price DCF -

RFL Dividends

No Dividends Paid

RFL Growth Ratios

Growth Correlation 3m 24%
Growth Correlation 12m 64.1%
Growth Correlation 5y -81.5%
CAGR 5y -30.72%
CAGR/Max DD 5y -0.31
Sharpe Ratio 12m -0.09
Alpha -0.44
Beta 0.41
Volatility 54.74%
Current Volume 15k
Average Volume 20d 19.5k
What is the price of RFL stocks?
As of March 18, 2025, the stock is trading at USD 1.83 with a total of 15,019 shares traded.
Over the past week, the price has changed by +1.67%, over one month by -12.44%, over three months by -3.43% and over the past year by +7.65%.
Is Rafael Holdings a good stock to buy?
No, based on ValueRay Fundamental Analyses, Rafael Holdings (NYSE:RFL) is currently (March 2025) a stock to sell. It has a ValueRay Fundamental Rating of -64.76 and therefor a negative outlook according to the companies health.
Based on ValueRays Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of RFL as of March 2025 is 1.37. This means that RFL is currently overvalued and has a potential downside of -25.14%.
Is RFL a buy, sell or hold?
Rafael Holdings has no consensus analysts rating.
What are the forecast for RFL stock price target?
According to ValueRays Forecast Model, RFL Rafael Holdings will be worth about 1.5 in March 2026. The stock is currently trading at 1.83. This means that the stock has a potential downside of -19.13%.
Issuer Forecast Upside
Wallstreet Target Price - -
Analysts Target Price - -
ValueRay Target Price 1.5 -19.1%